Pituitary, SIADH & DI

Tempting to pick somatostatin receptor inhibition since octreotide and lanreotide are the classic injectable pituitary-tumor drugs, but those target GH-secreting adenomas, not lactotroph cells. Think of dopamine as the hypothalamus's mute button on prolactin: a prolactinoma cuts the wire, and cabergoline plugs in a replacement wire directly at the D2 receptor on the tumor cell, re-engaging the mute. Correct: B.

Cabergoline is a D2 dopamine receptor agonist. Dopamine is the physiologic brake on prolactin secretion: hypothalamic dopamine (dopaminergic neurons of the tuberoinfundibular pathway) tonically suppresses lactotroph cells via D2 receptors. Prolactinomas escape this inhibition through tumor autonomy. Cabergoline mimics dopamine, re-engaging the D2 receptor, which inhibits prolactin synthesis via Gi signaling and directly causes tumor cell apoptosis and involution, shrinking the mass.

Option A (somatostatin receptor inhibition): Somatostatin receptors are the target of octreotide and lanreotide (injectable somatostatin analogs used for acromegaly and GH-secreting tumors), not the lactotroph cells that make prolactin. Prolactinoma cells do not meaningfully express the somatostatin receptor subtype (the specific receptor isoform that, when bound, shuts down hormone secretion) that matters for suppressing prolactin output, so these drugs would have negligible effect on prolactin levels or tumor size in this patient.
Break it down: Somatostatin analogs are the GH-tumor drug; cabergoline (the dopamine agonist) is the prolactinoma drug.

Option C (estrogen receptor blockade): While estrogen promotes prolactinoma growth (explaining their higher incidence in premenopausal women), blocking estrogen receptors does not reduce prolactin secretion or cause tumor involution. Estrogen receptor antagonists address the growth stimulus, not the secretory machinery, and would not explain the rapid prolactin normalization cabergoline produces within weeks.
Break it down: Estrogen blockade slows growth; it does not lower prolactin levels or shrink tumor through apoptosis.

Option D (GnRH receptor activation): Cabergoline has no direct action on GnRH (gonadotropin-releasing hormone) receptors. The restored menstrual cycles and LH/FSH (luteinizing hormone/follicle-stimulating hormone) normalization patients experience on cabergoline are downstream consequences of prolactin normalization: once prolactin falls, the hypothalamic GnRH pulse generator (the brain circuit that fires in bursts to drive the reproductive axis) restores itself. The question asks for the drug's primary mechanism, not its indirect downstream result.
Break it down: Gonadal axis restoration is the downstream result of fixing prolactin, not a separate drug target.

Tempting to pick serum sodium normalization since the goal of treating DI is to fix the sodium, but sodium shifts too slowly and too nonspecifically to distinguish central from nephrogenic DI. Think of the dDAVP challenge as a key test: in central DI the lock (V2 receptor on the collecting duct) is intact and the key was just missing; give dDAVP and the door opens immediately and urine concentrates. In nephrogenic DI the lock is broken, so even a perfect key produces nothing. Correct: C.

Central DI responds to exogenous ADH (dDAVP) because the problem is absent ADH production, not receptor dysfunction. The collecting duct V2 receptors are intact. When ADH is given, the collecting duct becomes permeable to water, urine concentrates by >50% (typically to >200 mOsm/kg), and urine output falls. This is the diagnostic breakpoint: central DI concentrates urine after dDAVP; nephrogenic DI does not, because the receptor or downstream aquaporin-2 (the water-channel protein that physically opens to let water through) signaling is broken.

Option A (serum sodium normalizes within 2 hours): Serum sodium correction is a slow downstream consequence, not an acute diagnostic marker. Even when dDAVP works perfectly, the kidneys must first stop the polyuria and then gradually reabsorb free water over hours to days. More critically, sodium normalization speed cannot distinguish central from nephrogenic DI because either type can show sodium changes depending on oral fluid intake.
Break it down: Serum sodium shifts too slowly and too nonspecifically to differentiate DI subtypes; the urine response is the actual test.

Option B (urine sodium increases above 40 mEq/L): ADH concentrates urine by pulling water through aquaporin-2 channels (protein pores in the collecting duct wall that open on command to let water flow back into the body) back into the body, not by actively retaining sodium. When urine volume shrinks, the same sodium is dissolved in less water, so urine sodium concentration may fall or stay flat while osmolality rises sharply. Urine sodium is not part of the standard dDAVP challenge interpretation, and a rise in urine sodium would not distinguish central from nephrogenic DI in any case.
Break it down: ADH acts on water channels, not sodium transporters; concentrated urine means less water, not more sodium retained.

Option D (serum osmolality decreases to below 290 mOsm/kg): Like option A, serum osmolality shifts happen downstream and slowly, well after the kidney has responded. A fall in serum osmolality could occur with any treatment that reduces free water losses (including increased oral intake) and tells you nothing about the kidney's receptor-level response to ADH. The acute, specific diagnostic signal is entirely in the urine osmolality response.
Break it down: Serum osmolality is a slow downstream signal; urine osmolality is where you read the kidney's answer to ADH.

Tempting to blame cerebral edema since hyponatremia and brain swelling are taught together, but cerebral edema comes from low sodium, not from correcting it , this patient's sodium went UP, and the new deficits appeared two days AFTER correction was complete. Think of brain cells in chronic hyponatremia as a submarine that has vented ballast to match low external pressure: correct the sodium too fast and the outside suddenly becomes saltier, the vented hull is crushed before it can reinflate. Correct: B.

Osmotic demyelination syndrome (ODS, formerly central pontine myelinolysis). The sodium rose 20 mEq/L in 12 hours, far exceeding the safe correction rate of 8-12 mEq/L per 24 hours. In chronic hyponatremia, brain cells adapt by extruding organic osmolytes (small molecules like glutamine, inositol, and taurine that act as internal ballast). Think of it like a submarine slowly venting ballast to equalize with outside pressure: the cells are already "deflated" to match their low-sodium environment. When sodium is corrected too quickly, the outside becomes suddenly saltier and water is yanked out of these already-adapted cells. Oligodendrocytes in the pons are particularly vulnerable, and the myelin sheaths they maintain are destroyed. Presentation is delayed 2-6 days because demyelination takes time to become clinically apparent, with dysarthria, dysphagia, and bilateral spasticity as classic findings.

Option A (re-accumulation of sodium causing cerebral edema): Cerebral edema from sodium imbalance is the risk of uncorrected hyponatremia, not of hyponatremia that was treated. Water enters brain cells when blood becomes hypotonic relative to the intracellular space, but this patient's sodium was raised from 108 to 128, moving in the correct direction. The patient was alert and oriented post-treatment, confirming no herniation event; the new deficit appeared two days after correction completed, which is not consistent with edema from the initial admission.
Break it down: Cerebral edema means sodium too low; this patient's sodium went up, ruling out that direction of injury.

Option C (hypertonic saline causing basilar artery vasospasm): Hypertonic saline does not cause arterial vasospasm through any established mechanism. Even if it could, basilar artery vasospasm presents as acute brainstem ischemia with sudden onset in seconds to minutes, not as a 2-day progressive syndrome. The delayed timeline is the critical discriminator: vascular events are instantaneous while demyelination takes days to manifest clinically.
Break it down: Vasospasm is acute and instantaneous; a 2-day delay rules out vascular etiology and points to a biological process.

Option D (autoimmune demyelination via complement activation): ODS is direct osmotic physical injury to oligodendrocytes, not an immune-mediated attack. There are no inflammatory cells in the ODS lesion, no myelin-specific antibodies, and no treatment response to steroids or immunotherapy. This mechanism would describe multiple sclerosis or NMOSD (neuromyelitis optica spectrum disorder); the distinction matters because MS and NMOSD can respond to IV methylprednisolone, while ODS does not.
Break it down: ODS is osmotic injury, not immune attack; no inflammatory cells, no steroid response, different MRI pattern from MS.

Tempting to pick pituitary adenoma since Cushing disease is the most common cause of ACTH-dependent hypercortisolism, but pituitary adenomas retain partial glucocorticoid feedback and would suppress on the high-dose dexamethasone test. Think of the high-dose dex test as a corporate override signal: pituitary tumors, even rebellious ones, still have a fax machine that can receive orders; ectopic SCLC tumors threw the fax machine out and operate with complete autonomy. Correct: C.

The high-dose dexamethasone suppression test exploits the fact that pituitary adenoma cells retain partial glucocorticoid feedback sensitivity, while ectopic ACTH-secreting tumors do not. In Cushing disease, high-dose dexamethasone suppresses cortisol by >50%. Ectopic sources (SCLC, bronchial carcinoid, thymoma) are autonomous and completely resistant to dexamethasone suppression. The markedly elevated ACTH (>300 pg/mL) and smoking history further support ectopic ACTH from lung malignancy, with SCLC (small cell lung cancer, the classic board source for ectopic ACTH) as the primary concern.

Option A (primary adrenal adenoma secreting cortisol autonomously): Primary adrenal adenomas produce cortisol without any ACTH instruction; they are ACTH-independent. All that free cortisol feeds back to suppress the pituitary, so serum ACTH would be very low or undetectable. This patient's ACTH is 380 pg/mL, the exact opposite of what primary adrenal disease produces. Markedly elevated ACTH always means the driver is upstream, either at the pituitary or an ectopic source.
Break it down: Adrenal autonomous cortisol suppresses the pituitary, so ACTH must be low in primary adrenal Cushing's.

Option B (pituitary adenoma with aggressive tumor biology): Pituitary ACTH-secreting adenomas retain partial negative feedback sensitivity, and this principle is the entire basis of the high-dose dexamethasone suppression test. Even aggressive corticotroph adenomas (ACTH-secreting pituitary tumors) show >50% cortisol suppression with 8mg dexamethasone. Non-suppression is the hallmark of ectopic ACTH, not of a more aggressive pituitary tumor. Additionally, ACTH values above 300 pg/mL are far more characteristic of ectopic secretion than of Cushing disease, and a heavy smoker with Cushingoid features has SCLC on the differential until proven otherwise.
Break it down: Cushing disease suppresses on high-dose dex even when aggressive; non-suppression at this ACTH level is ectopic, not pituitary.

Option D (pseudo-Cushing from alcohol): Pseudo-Cushing syndrome from alcohol causes mild hypercortisolism through HPA (hypothalamic-pituitary-adrenal) axis dysregulation, not autonomous ACTH overproduction. ACTH in pseudo-Cushing is typically normal to mildly elevated, not 380 pg/mL. Alcohol stimulates CRH (corticotropin-releasing hormone, the brain signal that tells the pituitary to make more ACTH) release, nudging the axis without generating a tumor-level autonomous signal. Pseudo-Cushing resolves with sobriety and would not produce non-suppression on high-dose dexamethasone the way an autonomous tumor does.
Break it down: Pseudo-Cushing mildly stresses the HPA axis and resolves with sobriety; 380 pg/mL ACTH is autonomous tumor output, not a stress response.